Ricardo Arteaga

[Journal of Clinical Oncology @JCO_ASCO]

Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia’s Landmark Tumor-Agnostic Immunotherapy Reimbursement. Co-authored by @VivekSubbiah and @Dr_R_Kurzrock.

Read the full article. https://t.co/zSm95XX5Xl

[Ricardo Arteaga @mcricardoa]

@PandaDelAmor22 @MunicipioOaxaca @grok que pasó con la mujer ?

[Instituto Nacional de Cancerología @incanMX]

7 de junio | Día Mundial del Superviviente de Cáncer

Hoy reconocemos la fortaleza, resiliencia y esperanza de quienes han enfrentado el cáncer. Su historia inspira y nos recuerda el valor de cada día y la importancia de acompañar, cuidar y seguir avanzando juntos. 🎗️✨

[Enrique Grande @drenriquegrande]

⚡️ Phase 3 KEYNOTE-B15/EV-304 at #ASCO26: perioperative EV + pembrolizumab vs gemcitabine/cisplatin in cisplatin-eligible MIBC.

EFS HR 0.53. pCR 55.8% vs 32.5%. OS HR 0.65.

First regimen in 25 years to surpass cisplatin-based neoadjuvant chemotherapy in MIBC.

@mattgalsky @ASCO #BladderCancer

https://t.co/7zGdhVKvdD

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

#ASCO26 abstr 3510
Onvansertib + Chemo + Bev in 1L RAS-mutated mCRC (rPh2 CRDF-004 trial)
💡Onvansertib: PLK1 inhibitor
◾️ORR: 72.2% vs 43.2%
◾️PFS: NR vs 10.97 mo (HR 0.37, p = 0.048)
👉Promising results! A Ph3 is warranted.
@ASCO @OncoAlert

[Ricardo Arteaga @mcricardoa]

@somosmitu Viva chicharito. Jamás dijo algo indignante. @CH14_

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#ASCO23 @ASCO @DrChoueiri present the data on Contact-3 trial which addresses a major question in the #mRCC #kidneycancer field 👉Is there a role of ICI Re-challenge? Answer is “NO”. This study does change my practice in many patients. Congrats for the simultaneous @theLancet publication led by @montypal 👇 @OncoAlert @kidneycan @urotoday

[SABCS @SABCSSanAntonio]

June is National Cancer Survivor Month. Did you know that there are 18 million cancer survivors in the U.S., and that more than 20 percent of those survivors are living with, through, or beyond a breast cancer diagnosis? Learn more: https://t.co/IQnfRKvBWN #CelebrateSurvivorship

[NEJM Evidence @NEJMEvidence]

Positive lumpectomy margins imply incomplete tumor removal and predict local breast cancer recurrence. This trial assessed margin status +/- pegulicianine fluorescence guided surgery for stages 0–III breast cancers. https://t.co/5cgVyWEAEB

#OncoAlert

[Ricardo Arteaga @mcricardoa]

Excelentes noticias para las mujeres diagnosticadas con cáncer de mama en terapia ayudante que desean tener hijos

[NEJM @NEJM]

In women with previous breast cancer who temporarily discontinued adjuvant endocrine therapy to attempt pregnancy, the frequency of breast cancer events was below the prespecified safety threshold and similar to that in controls (POSITIVE trial). https://t.co/zM3f4SbgjE

[Ricardo Arteaga @mcricardoa]

Lunes + Mayo = Día de concientización de Melanoma

Que mejor que una revisión ad hoc
https://t.co/uf04gecQbb

[Ricardo Arteaga @mcricardoa]

RTOG 0815 disponible en JCO.

RT de dosis escalada para el Ca de próstata de riesgo intermedio con ADT a corto plazo.

Seguimiento medio 6,3 años.

ADT redujo la falla de PSA, DM, PCSM, uso de terapia de rescate.

Supervivencia global ❌? Diría peendiente
https://t.co/oArvHgmrIv

[Ricardo Arteaga @mcricardoa]

Analizar antes de cortar en cáncer Renal. De acuerdo con sus conclusiones.

[Keith Kowalczyk, MD @KeithKow]

Dr. SHUCH! Bringing heat! Histology just as/more important than size when treating RCC. Great talk. @KidneyCancerDoc #AUA23

[Ricardo Arteaga @mcricardoa]

¿Otra molécula de Inmunoterapia?

Gran abanico de tratamiento para el Cáncer Renal Irresecable.

OR recuerda KN 426. Valorar perfil de EA.

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫RENOTORCH: COMBO Toripalimab Axitinib cumple con el objetivo principal en pacientes con RCC💫
@AACR @ASCO @NIH @pfizer @OncoReporte @OncoAlert
💫RENOTORCH: COMBO Toripalimab Axitinib Meets Primary Endpoint in RCC Patients💫 https://t.co/fhgFTRyRxK

[Ricardo Arteaga @mcricardoa]

Los antiandrogénicos de segunda generación cambiando la historia natural de la enfermedad en Cáncer de Próstata.

[Martín Angel @Martin_AngelMD]

EMBARK trial: enzalutamide combo Improve MFS (HR: 0.42 👏) delays in PSA progression (HR, 0.07 ‼️) , and time to new antineoplastic therapy (HR, 0.37 👏) #AUA23 @OncoAlert @OncoReporte @oncourologiaarg
Thanks @JuanCamean2 @DBarreiro4 for sharing knowledge.

[Ricardo Arteaga @mcricardoa]

La Inmunoterapia en cáncer de vejiga estableciendose cómo estándar de tratamiento

[Yüksel Ürün @DrYukselUrun]

JAVELIN Bladder 100 trial:
✅ Avelumab 1L maintenance + BSC significantly improves OS & PFS in aUC patients after 1L platinum-based chemo
✅ Consistent results across subgroups, incl. patients treated w/ cisplatin (fig A-B) or carboplatin (Fİg C-D) + gemcitabine
✅ Supports avelumab as standard-of-care
#cancerresearch @OncoAlert @EUplatinum @PGrivasMDPhD @OncoBellmunt @y_loriot @kalasri3 @cnsternberg @shilpaonc @tompowles1 @Uromigos
https://t.co/85JhGMr1SK

[Ricardo Arteaga @mcricardoa]

Toxicidad de tiempo por tratamiento: Porque no es lo mismo vida que calidad de vida y el tiempo que pasas en el hospital buscándola

https://t.co/cBRCmhalLn

[ACS Journal Cancer @JournalCancer]

The combination therapy of PD-1 inhibitors plus lenvatinib has promising survival benefits in the management of patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.

🔗 https://t.co/RKUX5BYL5I

@OncoAlert

[Matthias Scheffler @trnsltnl]

Happy to contribute, finally out: Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/PoPkMVi39V #LCSM @EGFRResisters

[Arndt Vogel @ArndtVogel]

🔥Risk & location of distant metastases in patients with advanced rectal cancer after total neoadjuvant treatment in the RAPIDO trial
https://t.co/LSSBpvqa7t
👉TNT decreases occurrence of (liver-) metastases, but this is counterbalanced by shorter post-recurrence OS
@myESMO @OncoAlert